Login to Your Account



Other News To Note


Monday, February 11, 2013
• OxOnc Development LP, of Princeton, N.J., said it entered a co-development agreement with Pfizer Inc., of New York, to conduct a pivotal trial of Pfizer's Xalkori (crizotinib) in patients with non-small-cell lung cancer harboring a ROS1 (c-ros) gene rearrangement).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription